| 
                                
                                    |    新型冠狀病毒(2019-nCoV)疫情正在迅速向全球蔓延。截止2020年3月6日,全球累計(jì)98373人, 累計(jì)死亡3388人。由于目前沒有特效藥可以治療新冠肺炎,治療新冠肺炎的藥物研發(fā)迫在眉睫。通過以AI為架構(gòu)的藥物篩選手段,可以發(fā)現(xiàn)多種可能對2019-nCoV有治療作用的藥物及化合物。阿拉丁提供以下幾十款試劑作為此藥物研發(fā)的研發(fā)用材料。 
      韓國Deargen公司、美國佐治亞州亞特蘭大市埃默里大學(xué)、韓國天安市擔(dān)國大學(xué)自然科學(xué)學(xué)院聯(lián),利用藥物-靶點(diǎn)相互作用模型(MT-DTI),預(yù)測了與新型冠狀病毒(2019-nCoV) 3C樣蛋白酶、RNA依賴RNA聚合酶、解旋酶、3 '- 5 '核酸外切酶、內(nèi)切RNA酶、內(nèi)切RNA酶的藥物及化合物。 
 抑制新型冠狀病毒(2019-nCoV) 3C樣蛋白酶的DTI預(yù)測結(jié)果
    
        
            | 項(xiàng)目號 | 產(chǎn)品名稱 | 純度 | CAS | 規(guī)格 |  
            | A125825 | Atazanavir 阿扎那韋
 | - | 198904-31-3 | 10mg,50mg,250mg,5g |  
            | E135556 | Efavirenz 依法韋侖
 | ≥98%(HPLC) | 154598-52-4 | 10mg,50mg,250mg,1g,5g |  
            | R126586 | 利托那韋 Ritonavir
 | ≥98% | 155213-67-5 | 10mg,50mg,250mg,500mg |  
            | D127636 | 多替拉韋 Dolutegravir
 | ≥99% | 1051375-16-6 | 5mg,10mg,50mg |  
            | A126103 | Asunaprevir 阿那匹韋
 | ≥98% | 630420-16-5 | 5mg,10mg,50mg,250mg |  
            | S127117 | Simeprevir 西咪匹韋
 | ≥99% | 923604-59-5 | 5mg,10mg,50mg,100mg |  抑制新型冠狀病毒(2019-nCoV)的RNA依賴RNA聚合酶的DTI預(yù)測結(jié)果
    
        
            | 項(xiàng)目號 | 產(chǎn)品名稱 | 純度 | CAS | 規(guī)格 |  
            | M124903 | MK-5172 | 98% | 1350514-68-9 | 5mg,10mg |  
            | G129109 | Ganciclovir 更昔洛韋
 | ≥98.0% | 82410-32-0 | 1g,5g,25g,100g |  
            | A125825 | Atazanavir 阿扎那韋
 | - | 198904-31-3 | 10mg,50mg,250mg,5g |  
            | D127186 | Daclatasvir(BMS-790052) | ≥98% | 1009119-64-5 | 10mg,50mg,250mg |  
            | E126710 | Etravirine (TMC125) | ≥95% | 269055-15-4 | 5mg,25mg,100mg,1g |  
            | E181466 | Entecavir 恩替卡韋
 | 98% | 142217-69-4 | 250mg,1g |  
            | E135556 | Efavirenz 依法韋侖
 | ≥98%(HPLC) | 154598-52-4 | 10mg,50mg,250mg,1g,5g |  
            | A126103 | Asunaprevir 阿那匹韋
 | ≥98% | 630420-16-5 | 5mg,10mg,50mg,250mg |  
            | A126552 | Abacavir 阿巴卡韋
 | ≥98.0% | 136470-78-5 | 1g,5g |  
            | D127636 | 多替拉韋 Dolutegravir
 | ≥99% | 1051375-16-6 | 5mg,10mg,50mg |  
            | V127611 | VX-222 (VCH-222, Lomibuvir) | ≥99% | 1026785-59-0 | 5mg,10mg,50mg |  
            | P125160 | Penciclovir 噴昔洛韋
 | ≥99% | 39809-25-1 | 50mg,250mg,1g |  
            | D127014 | Danoprevir (ITMN-191) | ≥95% | 850876-88-9 | 2mg,5mg,25mg |  
            | R126586 | 利托那韋 Ritonavir
 | ≥98% | 155213-67-5 | 10mg,50mg,250mg,500mg |  
            | S126514 | 沙奎那韋 Saquinavir
 | ≥98% | 127779-20-8 | 25mg,100mg |  
            | R129802 | Raltegravir(MK-0518) | ≥97% | 518048-05-0 | 5mg,10mg,50mg,1g |  抑制新型冠狀病毒(2019-nCoV)的解旋酶的DTI預(yù)測結(jié)果
    
        
            | 項(xiàng)目號 | 中文名稱 | 規(guī)格 | CAS | 包裝 |  
            | S127117 | Simeprevir 西咪匹韋
 | ≥99% | 923604-59-5 | 5mg,10mg,50mg,100mg |  
            | A125825 | Atazanavir 阿扎那韋
 | - | 198904-31-3 | 10mg,50mg,250mg,5g |  
            | M124903 | MK-5172 | 98% | 1350514-68-9 | 5mg,10mg |  
            | A126103 | Asunaprevir 阿那匹韋
 | ≥98% | 630420-16-5 | 5mg,10mg,50mg,250mg |  
            | T126775 | Telaprevir 特拉匹韋
 | ≥98% | 402957-28-2 | 5mg,10mg,50mg |  
            | R126586 | 利托那韋 Ritonavir
 | ≥98% | 155213-67-5 | 10mg,50mg,250mg,500mg |  
            | L299096 | 洛比那韋 Lopinavir
 | 95% | 192725-17-0 | 10mg,50mg,250mg,1g |  
            | L129320 | 洛比那韋 Lopinavir
 | ≥99% | 192725-17-0 | 10mg,50mg,100mg,250mg,1g |  
            | D125841 | 達(dá)蘆那韋 Darunavir
 | 98% | 206361-99-1 | 5mg,10mg,50mg,250mg,1g |  
            | G129109 | Ganciclovir 更昔洛韋
 | ≥98.0% | 82410-32-0 | 1g,5g,25g,100g |  
            | P125160 | Penciclovir 噴昔洛韋
 | ≥99% | 39809-25-1 | 50mg,250mg,1g |  
            | E126710 | Etravirine (TMC125) | ≥95% | 269055-15-4 | 5mg,25mg,100mg,1g |  
            | R129802 | Raltegravir(MK-0518) | ≥97% | 518048-05-0 | 5mg,10mg,50mg,1g |  
            | D127636 | 多替拉韋 Dolutegravir
 | ≥99% | 1051375-16-6 | 5mg,10mg,50mg |  
            | N137745 | 奈非那韋 Nelfinavir Mesylate
 | 98% | 159989-65-8 | 10mg,50mg,250mg |  
            | E135556 | Efavirenz 依法韋侖
 | ≥98%(HPLC) | 154598-52-4 | 10mg,50mg,250mg,1g,5g |  
            | E181466 | Entecavir 恩替卡韋
 | 98% | 142217-69-4 | 250mg,1g |  
            | R126586 | 利托那韋 Ritonavir
 | ≥98% | 155213-67-5 | 10mg,50mg,250mg,500mg |  
            | V127611 | VX-222 (VCH-222, Lomibuvir) | ≥99% | 1026785-59-0 | 5mg,10mg,50mg |  抑制新型冠狀病毒(2019-nCoV)的3 '- 5 '核酸外切酶的DTI預(yù)測結(jié)果
    
        
            | 項(xiàng)目號 | 中文名稱 | 規(guī)格 | CAS | 包裝 |  
            | S127117 | Simeprevir 西咪匹韋
 | ≥99% | 923604-59-5 | 5mg,10mg,50mg,100mg |  
            | E135556 | Efavirenz 依法韋侖
 | ≥98%(HPLC) | 154598-52-4 | 10mg,50mg,250mg,1g,5g |  
            | D127014 | Danoprevir (ITMN-191) | ≥95% | 850876-88-9 | 2mg,5mg,25mg |  
            | G129109 | Ganciclovir 更昔洛韋
 | ≥98.0% | 82410-32-0 | 1g,5g,25g,100g |  
            | P125160 | Penciclovir 噴昔洛韋
 | ≥99% | 39809-25-1 | 50mg,250mg,1g |  
            | A125825 | Atazanavir 阿扎那韋
 | - | 198904-31-3 | 10mg,50mg,250mg,5g |  
            | E181466 | Entecavir 恩替卡韋
 | 98% | 142217-69-4 | 250mg,1g |  
            | D127186 | Daclatasvir(BMS-790052) | ≥98% | 1009119-64-5 | 10mg,50mg,250mg |  
            | M124903 | MK-5172 | 98% | 1350514-68-9 | 5mg,10mg |  
            | A126103 | Asunaprevir 阿那匹韋
 | ≥98% | 630420-16-5 | 5mg,10mg,50mg,250mg |  
            | R126586 | 利托那韋 Ritonavir
 | ≥98% | 155213-67-5 | 10mg,50mg,250mg,500mg |  
            | V127611 | VX-222 (VCH-222, Lomibuvir) | ≥99% | 1026785-59-0 | 5mg,10mg,50mg |  
            | D125841 | 達(dá)蘆那韋 Darunavir
 | 98% | 206361-99-1 | 5mg,10mg,50mg,250mg,1g |  
            | R129802 | Raltegravir(MK-0518) | ≥97% | 518048-05-0 | 5mg,10mg,50mg,1g |  
            | D127636 | 多替拉韋 Dolutegravir
 | ≥99% | 1051375-16-6 | 5mg,10mg,50mg |  
            | L299096 | 洛比那韋 Lopinavir
 | 95% | 192725-17-0 | 10mg,50mg,250mg,1g |  
            | L129320 | 洛比那韋 Lopinavir
 | ≥99% | 192725-17-0 | 10mg,50mg,100mg,250mg,1g |  抑制新型冠狀病毒(2019-nCoV)的內(nèi)切RNA酶的DTI預(yù)測結(jié)果
    
        
            | 項(xiàng)目號 | 中文名稱 | 規(guī)格 | CAS | 包裝 |  
            | E135556 | Efavirenz 依法韋侖
 | ≥98%(HPLC) | 154598-52-4 | 10mg,50mg,250mg,1g,5g |  
            | A125825 | Atazanavir 阿扎那韋
 | - | 198904-31-3 | 10mg,50mg,250mg,5g |  
            | R126586 | 利托那韋 Ritonavir
 | ≥98% | 155213-67-5 | 10mg,50mg,250mg,500mg |  
            | D127014 | Danoprevir (ITMN-191) | ≥95% | 850876-88-9 | 2mg,5mg,25mg |  
            | M124903 | MK-5172 | 98% | 1350514-68-9 | 5mg,10mg |  
            | D127636 | 多替拉韋 Dolutegravir
 | ≥99% | 1051375-16-6 | 5mg,10mg,50mg |  
            | V127611 | VX-222 (VCH-222, Lomibuvir) | ≥99% | 1026785-59-0 | 5mg,10mg,50mg |  
            | L299096 | 洛比那韋 Lopinavir
 | 95% | 192725-17-0 | 10mg,50mg,250mg,1g |  
            | L129320 | 洛比那韋 Lopinavir
 | ≥99% | 192725-17-0 | 10mg,50mg,100mg,250mg,1g |  
            | D125841 | 達(dá)蘆那韋 Darunavir
 | 98% | 206361-99-1 | 5mg,10mg,50mg,250mg,1g |  
            | N137745 | 奈非那韋 Nelfinavir Mesylate
 | 98% | 159989-65-8 | 10mg,50mg,250mg |  
            | T126775 | Telaprevir 特拉匹韋
 | ≥98% | 402957-28-2 | 5mg,10mg,50mg |  
            | A126552 | Abacavir 阿巴卡韋
 | ≥98.0% | 136470-78-5 | 1g,5g |  
            | R129802 | Raltegravir(MK-0518) | ≥97% | 518048-05-0 | 5mg,10mg,50mg,1g |  抑制新型冠狀病毒(2019-nCoV)的2’-O-核糖 甲基轉(zhuǎn)移酶的DTI預(yù)測結(jié)果
    
        
            | 項(xiàng)目號 | 中文名稱 | 規(guī)格 | CAS | 包裝 |  
            | E135556 | Efavirenz 依法韋侖
 | ≥98%(HPLC) | 154598-52-4 | 10mg,50mg,250mg,1g,5g |  
            | A125825 | Atazanavir 阿扎那韋
 | - | 198904-31-3 | 10mg,50mg,250mg,5g |    參考文獻(xiàn) Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model.       |  |